These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36348577)

  • 41. Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?
    Ahmed ME; Mahmoud AM; Reitano G; Zeina W; Lehner K; Day CA; Riaz I; Childs DS; Orme JJ; Tuba Kendi A; Johnson GB; Jeffrey Karnes R; Kwon ED; Andrews JR
    Eur Urol Open Sci; 2024 Aug; 66():38-45. PubMed ID: 39040620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of the location and number of metastases in the survival of metastatic prostatic cancer patients.
    Guijarro A; Hernández V; de la Morena JM; Jiménez-Valladolid I; Pérez-Fernández E; de la Peña E; Llorente C
    Actas Urol Esp; 2017 May; 41(4):226-233. PubMed ID: 27773340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.
    Eichhorn F; Klotz LV; Muley T; Kobinger S; Winter H; Eichhorn ME
    Lung Cancer; 2019 Dec; 138():95-101. PubMed ID: 31678832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection.
    Puterman C; Bjöersdorff M; Amidi J; Anand A; Soller W; Jiborn T; Kjölhede H; Trägårdh E; Bjartell A
    Scand J Urol; 2021 Aug; 55(4):293-297. PubMed ID: 33939583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
    Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
    Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases.
    Lunger L; Steinhelfer L; Korn P; Eiber M; Maurer T; Büchler J; Horn T; Gschwend JE; Heck MM
    Eur Urol Oncol; 2023 Feb; 6(1):95-98. PubMed ID: 36604297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
    Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
    Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
    Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
    J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
    Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
    Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
    Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
    Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subphrenic Lymph Node Metastasis Predicts Poorer Prognosis for Nasopharyngeal Carcinoma Patients With Metachronous Metastasis.
    Zhang XF; Zhang Y; Liang XW; Chen JL; Zhi SF; Yin WJ; Wang MY; Dong EL; Chen DP
    Front Oncol; 2021; 11():726179. PubMed ID: 34660291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
    Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
    Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage.
    Kang MJ; Jang JY; Chang YR; Kwon W; Jung W; Kim SW
    Ann Surg Oncol; 2014 May; 21(5):1545-51. PubMed ID: 24419758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stage IVb thymic carcinoma: patients with lymph node metastases have better prognoses than those with hematogenous metastases.
    Yang Y; Fan XW; Wang HB; Xu Y; Li DD; Wu KL
    BMC Cancer; 2017 Mar; 17(1):217. PubMed ID: 28347273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
    JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dedifferentiation in the metastatic progression of prostate carcinoma.
    Cheng L; Slezak J; Bergstralh EJ; Cheville JC; Sweat S; Zincke H; Bostwick DG
    Cancer; 1999 Aug; 86(4):657-63. PubMed ID: 10440694
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
    Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases.
    Zhang P; Chen T; Yang M
    Urol Oncol; 2024 May; 42(5):160.e1-160.e10. PubMed ID: 38433022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.